Business Wire

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA ® ▼ (Dinutuximab Beta) in China

Share

EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Application (BLA) for QARZIBA®▼ (dinutuximab beta) was accepted by the China National Medical Products Administration (NMPA) and granted priority review. Dinutuximab beta is a targeted immunotherapy approved by the European Medicines Agency (EMA) for the treatment of high-risk neuroblastoma in patients aged 12 months and above who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma with or without residual disease. High-risk neuroblastoma is an aggressive neoplasm and the most common childhood solid tumour that originates outside of the brain. Dinutuximab beta is listed in the first batch of New Drugs in Urgent Clinical Need Marketed Overseas by the NMPA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201109005558/en/

“Dinutuximab beta represents an important biologic, which is already available to patients with high-risk neuroblastoma in Europe,” commented Xiaobin Wu, Ph.D., General Manager of China and President of BeiGene. “For paediatric patients fighting this disease in China, we are hopeful that dinutuximab beta will soon be available as a new treatment option. Our collaboration with EUSA and the progress thus far demonstrate our joint commitment to bringing high-quality therapies to the people who need them.”

Lee Morley, Chief Executive Officer of EUSA Pharma, said, “This milestone brings us and BeiGene closer to delivering on our promise of bringing innovative cancer and rare disease therapies to patients around the world. We look forward to working with BeiGene and the NMPA to potentially make dinutuximab beta available in China.”

About QARZIBA®▼ (dinutuximab beta)

QARZIBA®▼ is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells. Dinutuximab beta was approved by the European Commission in 2017 and is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures. In patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, dinutuximab beta should be combined with interleukin-2 (IL-2).

About EUSA Pharma

Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease. The company has extensive commercial operations in the United States and Europe, alongside a direct presence in select other markets across the globe. EUSA Pharma is led by an experienced management team with a strong record of building successful pharmaceutical companies and is supported by significant funding raised from leading life science investor EW Healthcare Partners. For more information please visit www.eusapharma.com.

About BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,700+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.

BeiGene Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential approval, launch and opportunity of QARZIBA® in China, future development and potential commercialization activities of the products under the agreement with EUSA, and other information that is not historical information. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

GL-DNB-2000070. November 2020

Contact information

EUSA Media
Rebecca Kerr
+44 7909 703627
media@eusapharma.com

BeiGene Investors
Craig West
+1 857-302-5189
ir@beigene.com

BeiGene Media
Liza Heapes
+1 857-302-5663
media@beigene.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PMI Commits to Disability Inclusion by Joining The Valuable 5003.12.2020 09:05:00 CETPress release

Philip Morris International Inc.(PMI) (NYSE: PM) today announced that CEO André Calantzopoulos has joined The Valuable 500—a global movement putting disability inclusion on the business leadership agenda. Signing on to this initiative marks another significant step in PMI’s journey of advancing inclusion and diversity in the workplace. André Calantzopoulos said: “Businesses with a global operating footprint, such as PMI, can make a meaningful impact by ensuring that everyone—including individuals with a disability—can prosper in the workplace. By signing The Valuable 500, I am proud to join forces with a host of other CEOs who are challenging their organizations and the business world to broaden the focus of their inclusion and diversity efforts, and to help create a more inclusive world for the 1.3 billion people with disabilities. This is the right thing to do as part of our broader work to create a more equitable society. And it is also the smart thing to do, allowing PMI to tap int

Siemens Smart Infrastructure Chooses AWS as Its Preferred Cloud Provider for SAP Environments3.12.2020 09:01:00 CETPress release

Today, Amazon Web Services (AWS), an Amazon.com company (NASDAQ: AMZN), announced that Siemens Smart Infrastructure, a business of the Siemens AG group focusing on energy distribution and intelligent buildings, is moving its SAP infrastructure to AWS. The business will migrate over 20 Enterprise Resource Planning (ERP) and Supply Chain Management (SCM) systems,based on SAP HANA, to AWS before the end of 2021. These systems support business-critical processes in areas such as manufacturing, operations, and sales across different business units including Building Products, Electrical Products, Digital Grid, and Distribution Systems. Moving these workloads to AWS will enable Siemens Smart Infrastructure to significantly shorten hardware refresh cycles, increase agility to test and deploy new systems, and provide the foundation for the company’s future transformation using SAP S/4HANA technology. This is the first migration of production-scale SAP systems to the cloud across the Siemens AG

ADVA and 6WIND deliver complete uCPE solution with high-performance routing3.12.2020 09:00:00 CETPress release

ADVA (FSE) today announced a partnership with 6WIND to deliver a high-performance and lightweight uCPE solution. Built on ADVA’s Ensemble Connector and including 6WIND routing technology, the offering provides communication service providers (CSPs) and enterprises with a complete uCPE platform. Now customers can deploy a comprehensive access solution optimized for edge cloud architecture that offers new levels of efficiency as well as future-proof scalability. The joint solution has already been selected by the German CSP WiTCOM to power its edge cloud smart city initiative, enabling services including IoT, traffic control and surveillance. “We’re joining forces with ADVA to build on our industry-leading position in uCPE. The partnership augments our current uCPE infrastructure offering with targeted applications that focus on providing complete, end-to-end networking and hosting capabilities,” said Julien Dahan, CEO, 6WIND. “With the embedding of our high-performance, ready-to-use sof

ESI Contributes to Nissan’s Breakthrough in Carbon Fiber Parts Production for Safer and Lighter Vehicles3.12.2020 08:15:00 CETPress release

ESI Group (Paris:ESI), global player in Virtual Prototyping software and services for industry, supports Nissan Motor Co in its production process that speeds up the development of car parts made from carbon fiber reinforced plastics (CFRP). Light yet extremely strong, this material will be used to make safer and more fuel-efficient cars. Safety, comfort and autonomy are key outcomes for consumers. To face this situation, automakers continuously innovate in different fields such as lightweight to help them achieve their expected results. For this purpose, the use of new materials can be key. Commonly used in other industries such as Aerospace and with promising capabilities, Carbon Fiber Reinforced Plastics (CFRP) were too time-consuming and too expensive to industrialize for the Automotive sector.“We have always considered CFRP as a material for future generations of cars. But when it comes to reality, CFRP can be used only for limited models and appears to be more challenging for mas

Thales Reinvents the Way Identity Documents Are Checked With Its Double-Sided ID Card Reader3.12.2020 08:00:00 CETPress release

Thales showcases the world’s only double-sided ID card reader, the first to be able to examine ID cards or driving licenses in the cloud1 in less than four seconds. The design of the intelligent reader allows to speed up the process, while guaranteeing a high security level, and offering cost benefits to the operators. It simplifies the process of ID verification and offers a touchless check, which is all the more important in the Covid-19 era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201202005045/en/ (Photo: Thales) The https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.thalesgroup.com%2Fen%2Fmarkets%2Fdigital-identity-and-security%2Fgovernment%2Fdocument-readers%2Fcr5400i&esheet=52337006&newsitemid=20201202005045&lan=en-US&anchor=Thales+Gemalto+Intelligent+Double-sided+ID+Card+Reader+CR5400i&index=1&md5=04bb2b3201d5fd5c98713db5a3d2e507 Thales Gemalto Intelligent Double-sided ID Card ReaderCR5400ien

Global Electronic Toll Collection and Road Usage Charging market to reach €490 billion in 20302.12.2020 17:06:00 CETPress release

As the UK government just announced it is considering Road Usage Charging (RUC) as a funding solution for its road network, RUC schemes are being pushed ahead around the world. In the US, Asia, Africa and Oceania, electronic tolling is becoming crucial to bridge financing gaps and substitute declining gas tax receipts. PTOLEMUS Consulting Group forecasts that 874 million global subscriptions in ETC/RUC schemes will be active by 2030, collecting over €490 billion every year by 2030. PTOLEMUS’ Electronic Tolling Global Study is the 3rd edition of its highly popular Electronic Tolling series of reports, and represents the most comprehensive review of the global ETC/RUC market to-date, including 950 pages of insights, data, analyses and forecasts. PTOLEMUS expects the global ETC/RUC market to grow at 13% CAGR to 2030, driven by multiple factors including: environmental policy, economic development, interoperability schemes and growth of cashless payments, propelled by COVID-19. Dr Andrew J